FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2110052844> ?p ?o ?g. }

• W2110052844 endingPage "190" @default.
• W2110052844 startingPage "184" @default.
• W2110052844 abstract "A recombinant humanized anti-IgE mAb, omalizumab, forms complexes with free IgE, blocking its interaction with mast cells and basophils; as a consequence, it might be effective in the treatment of asthma.The purpose of this study was to evaluate the efficacy and safety of omalizumab in the treatment of inhaled corticosteroid-dependent asthma.In this phase III, double-blinded, placebo-controlled trial, 525 subjects with severe allergic asthma requiring daily inhaled corticosteroids were randomized to receive placebo or omalizumab subcutaneously every 2 or 4 weeks, depending on baseline IgE level and body weight. Inhaled corticosteroid doses were kept stable over the initial 16 weeks of treatment and tapered during a further 12-week treatment period.Omalizumab treatment resulted in significantly fewer asthma exacerbations per subject and in lower percentages of subjects experiencing an exacerbation than placebo treatment during the stable steroid phase (0.28 vs 0.54 [P =.006] and 14.6% vs 23.3% [P =.009], respectively) and during the steroid reduction phase (0.39 vs 0.66 [P =.003] and 21.3% vs 32.3% [P =.004], respectively). Beclomethasone dipropionate reduction was significantly greater with omalizumab treatment than with placebo (median 75% vs 50% [P <.001]), and beclomethasone dipropionate discontinuation was more likely with omalizumab (39.6% vs 19.1% [P <.001]). Improvements in asthma symptoms and pulmonary function occurred along with a reduction in rescue beta-agonist use. Omalizumab was well tolerated, with an adverse-events profile similar to that of placebo.The addition of omalizumab to standard asthma therapy reduces asthma exacerbations and decreases inhaled corticosteroid and rescue medication use." @default.
• W2110052844 created "2016-06-24" @default.
• W2110052844 creator A5013167015 @default.
• W2110052844 creator A5021417774 @default.
• W2110052844 creator A5022249393 @default.
• W2110052844 creator A5044980958 @default.
• W2110052844 creator A5048635829 @default.
• W2110052844 creator A5072324527 @default.
• W2110052844 creator A5072735506 @default.
• W2110052844 creator A5079627419 @default.
• W2110052844 date "2001-08-01" @default.
• W2110052844 modified "2023-10-11" @default.
• W2110052844 title "Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma" @default.
• W2110052844 cites W1835232554 @default.
• W2110052844 cites W1910182345 @default.
• W2110052844 cites W1990470211 @default.
• W2110052844 cites W2009376119 @default.
• W2110052844 cites W2024931925 @default.
• W2110052844 cites W2047251211 @default.
• W2110052844 cites W2053591346 @default.
• W2110052844 cites W2065071227 @default.
• W2110052844 cites W2111105715 @default.
• W2110052844 cites W2136060598 @default.
• W2110052844 cites W2312397711 @default.
• W2110052844 cites W2329314791 @default.
• W2110052844 cites W4238331629 @default.
• W2110052844 doi "https://doi.org/10.1067/mai.2001.117880" @default.
• W2110052844 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11496232" @default.
• W2110052844 hasPublicationYear "2001" @default.
• W2110052844 type Work @default.
• W2110052844 sameAs 2110052844 @default.
• W2110052844 citedByCount "1109" @default.
• W2110052844 countsByYear W21100528442012 @default.
• W2110052844 countsByYear W21100528442013 @default.
• W2110052844 countsByYear W21100528442014 @default.
• W2110052844 countsByYear W21100528442015 @default.
• W2110052844 countsByYear W21100528442016 @default.
• W2110052844 countsByYear W21100528442017 @default.
• W2110052844 countsByYear W21100528442018 @default.
• W2110052844 countsByYear W21100528442019 @default.
• W2110052844 countsByYear W21100528442020 @default.
• W2110052844 countsByYear W21100528442021 @default.
• W2110052844 countsByYear W21100528442022 @default.
• W2110052844 countsByYear W21100528442023 @default.
• W2110052844 crossrefType "journal-article" @default.
• W2110052844 hasAuthorship W2110052844A5013167015 @default.
• W2110052844 hasAuthorship W2110052844A5021417774 @default.
• W2110052844 hasAuthorship W2110052844A5022249393 @default.
• W2110052844 hasAuthorship W2110052844A5044980958 @default.
• W2110052844 hasAuthorship W2110052844A5048635829 @default.
• W2110052844 hasAuthorship W2110052844A5072324527 @default.
• W2110052844 hasAuthorship W2110052844A5072735506 @default.
• W2110052844 hasAuthorship W2110052844A5079627419 @default.
• W2110052844 hasBestOaLocation W21100528441 @default.
• W2110052844 hasConcept C126322002 @default.
• W2110052844 hasConcept C141105273 @default.
• W2110052844 hasConcept C142724271 @default.
• W2110052844 hasConcept C159654299 @default.
• W2110052844 hasConcept C197934379 @default.
• W2110052844 hasConcept C203014093 @default.
• W2110052844 hasConcept C204787440 @default.
• W2110052844 hasConcept C27081682 @default.
• W2110052844 hasConcept C2776042228 @default.
• W2110052844 hasConcept C2776804153 @default.
• W2110052844 hasConcept C2777014857 @default.
• W2110052844 hasConcept C2778564945 @default.
• W2110052844 hasConcept C2778715236 @default.
• W2110052844 hasConcept C71924100 @default.
• W2110052844 hasConcept C90924648 @default.
• W2110052844 hasConceptScore W2110052844C126322002 @default.
• W2110052844 hasConceptScore W2110052844C141105273 @default.
• W2110052844 hasConceptScore W2110052844C142724271 @default.
• W2110052844 hasConceptScore W2110052844C159654299 @default.
• W2110052844 hasConceptScore W2110052844C197934379 @default.
• W2110052844 hasConceptScore W2110052844C203014093 @default.
• W2110052844 hasConceptScore W2110052844C204787440 @default.
• W2110052844 hasConceptScore W2110052844C27081682 @default.
• W2110052844 hasConceptScore W2110052844C2776042228 @default.
• W2110052844 hasConceptScore W2110052844C2776804153 @default.
• W2110052844 hasConceptScore W2110052844C2777014857 @default.
• W2110052844 hasConceptScore W2110052844C2778564945 @default.
• W2110052844 hasConceptScore W2110052844C2778715236 @default.
• W2110052844 hasConceptScore W2110052844C71924100 @default.
• W2110052844 hasConceptScore W2110052844C90924648 @default.
• W2110052844 hasIssue "2" @default.
• W2110052844 hasLocation W21100528441 @default.
• W2110052844 hasLocation W21100528442 @default.
• W2110052844 hasOpenAccess W2110052844 @default.
• W2110052844 hasPrimaryLocation W21100528441 @default.
• W2110052844 hasRelatedWork W1771951718 @default.
• W2110052844 hasRelatedWork W1980438888 @default.
• W2110052844 hasRelatedWork W2054139100 @default.
• W2110052844 hasRelatedWork W2089505012 @default.
• W2110052844 hasRelatedWork W2131115843 @default.
• W2110052844 hasRelatedWork W229245210 @default.
• W2110052844 hasRelatedWork W2402139063 @default.
• W2110052844 hasRelatedWork W2421625876 @default.
• W2110052844 hasRelatedWork W3137322934 @default.

• next